Wave Life Sciences: FDA Feedback Supports Genetic Disease Treatment Plan

Wave Life Sciences announced that feedback from the U.S. Food and Drug Administration will aid its planned registrational pathway for WVE-006, an RNA editing medicine targeting alpha-1 antitrypsin deficiency. The company believes this could lead to a quicker approval for the treatment of the rare liver and lung condition.